行情

TROV

TROV

Trovagene
NASDAQ

实时行情|Nasdaq Last Sale

1.710
-0.140
-7.57%
盘后: 1.650 -0.06 -3.51% 16:24 09/18 EDT
开盘
1.850
昨收
1.850
最高
1.890
最低
1.610
成交量
24.41万
成交额
--
52周最高
9.65
52周最低
1.300
市值
1,057.20万
市盈率(TTM)
-0.4284
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TROV 新闻

  • 50 Stocks Moving In Thursday's Mid-Day Session
  • Benzinga.6天前
  • 33 Stocks Moving in Thursday's Pre-Market Session
  • Benzinga.6天前
  • 美FDA抨击电子烟制造商Juul非法营销 威胁处以罚款
  • 新浪美股.09/09 17:48
  • IMF将考虑任命克里斯塔利娜-格奥尔基耶娃担任总裁
  • 新浪美股.09/09 17:23

更多

所属板块

医疗设备、用品及经销
+0.29%
医疗设备和用品
+0.41%

热门股票

名称
价格
涨跌幅

TROV 简况

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.
展开

Webull提供TrovaGene Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。